Kara 360-514-3940
Chris 360-514-6499

The oncologists at the PeaceHealth Southwest Cancer Center serve as investigators in clinical trials, sponsored by the National Cancer Institute, to advance the understanding and treatment of cancer. When applicable, you may be offered participation in one of these trials. This is entirely optional. For more information read our Frequently Asked Questions.

All Non-Metastatic Cancers

  • U16092 Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Non-Metastatic Cancer


  • A071701 Genomically-Guided Treatment Trial in Brain Metastases from any solid tumor - central screening for alteration in CDK pathway, P13K/AKT/mTOR pathway, and NTRK/ROS1 translocation.
  • A071702 A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
  • N0577 (CODEL) Phase III Intergroup Study of RT with Concomitant and Adjuvant Temozolomide vs. RT with Adjuvant PCV Chemotherapy in patients with 1p/19q Co-deleted Anaplastic Glioma or Low grade Glioma


  • A011202 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  • A011801 The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double Blinded Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
  • NRG-BR003 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or Without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
  • NRG-BR004   A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER2-Positive Metastatic Breast Cancer
  • EA1131 Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
  • EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
  • S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients with Metastatic HER-2-Positive Breast Cancer
  • S1703  Serum Tumor marker Directed Disease Monitoring in patients with Hormone Receptor positive HER2 Negative Metastatic Breast Cancer
  • S1706  A Phase II Randomized Trial of Olaparib (NSC-747856) Administered concurrently with RT vs. RT alone for Inflammatory Breast Cancer
  • URCC-18007 Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue in stage I-III breast cancer survivors


  • NCICOVID NCI COVID-19 in cancer patients study (N-CCaPS): A longitudinal natural history study


  • A021502 Combination Chemotherapy with or Without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • A021602    Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors previously Treated with Everolimus that are locally advanced, metastatic or cannot be removed by surgery
  • A021703 Randomized Double Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
  • A221805 Duloxetine to prevent Oxaliplatin-induced peripheral neuropathy: A Randomized, Double blind placebo controlled phase II study
  • EA2165 Randomized Phase II Study of Nivolumab after combined modality Therapy (CMT) in High Risk Anal Cancer(stage II-IIIB)
  • EA2174 A Phase II/III study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
  • EA2176 A Phase III Study of Immune Checkpoint inhibition with chemotherapy in treatment naive metastatic anal cancer patients
  • EA2182 A Randomized Phase II study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
  • EA2183 A Phase III study of consolidative radiotherapy in patients with Oligometastatic HER2 negative esophageal and gastric adenocarcinoma
  • EA2185 Comparing the clinical impact of pancreatic cyst surveillance programs
  • EA2186  A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients (70 and older) with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
  • EA2187 A Phase 2 Study of Pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma
  • GI005 Phase II/III study of Circulating tumor DNA as a predictive Biomarker in adjuvant chemotherapy in stage IIA colon cancer (COBRA)
  • S0820 Adenoma and Second Primary Prevention Trial
  • S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab compared to Cetuximab and Irinotecan in Advanced/Metastatic Colorectal Cancer with HER2 Amplification
  • S1922 Randomized Phase II Selection Study of Ramucirumab and Paclitaxel vs. FOLFIRI in refractory small bowel adenocarcinoma


  • A021804 A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
  • A031501 Pembrolizumab in Treating Patients with Locally Advanced Bladder Cancer
  • A031702 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers
  • A031704 PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal cell cancer
  • A031803 Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the treatment of patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
  • AGCT1531 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors  
  • SWOG S1815  Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers
  • NCT01226004   Multi-Institutional Registry for Prostate Cancer Radiosurgery- (PHSW only)


  • AGCT1531 A Phase III Study of Active surveillance for low risk and a Randomized Trial of Carboplatin vs. Cisplatin for standard Risk Pediatric and Adult Patients with Germ Cell Tumors <50 years of age
  • GOG0263 Radiation Therapy with or Without Chemotherapy in Patients with Stage I or Stage IIA Cervical Cancer Who Previously Underwent Surgery
  • GY009 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP supplied Bevacizumab and CTEP supplied Atezoluzumab versus Pegylated Liposomal Doxorubicin and CTEP supplied Bevacizumab in Platinum resistant Ovarian Cancer
  • GY019 A Randomized Phase III, Two-arm trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole monotherapy in Patients with Stage II-IV, Primary Low grade Serous Carcinoma of the Ovary or Peritoneum

Head & Neck 

  • EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • EA3161 A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in patients with Locally Advanced, Intermediate Risk HPV Positive Oropharyngeal Cancer
  • NRG HN007 An open Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the first-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma


  • A151216 Adjuvant Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
  • A081801 Integration of Immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO
  • E4512 Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • A171901 Older NSCLC patients (>/= 70 years of age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologists/patients choice)
  • EA5163 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
  • EA5181 Randomized Phase III trial of MEDI4736 (Durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC
  • EA5182 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
  • EA5191 A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Vs. Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
  • SWOG S1929 Phase II Randomized Study of Maintenance Atezolizumab Vs. Atezolizumab in Combination with Talazoparib in patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
  • SWOG S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC 783608) + SBRT vs. SBRT alone in High Risk, Early Stage NSCLC


  • A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
  • A041701  A Randomized Phase II/III Study of Conventional chemotherapy +/- Uproleselan in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction chemotherapy
  • A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
  • A041703 A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
  • ACCL16N1CD Cancer Care Delivery in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
  • EA9161 A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
  • EA9181 A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumombab for Newly Diagnosed BCR-ABL-Positive ALL in adults
  • S1712  Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating patients with Chronic Myeloid Leukemia


  • A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in patients with relapsed or refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
  • A051701 Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas
  • EA4151 Rituximab with or Without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
  • E4412  A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
  • EA4181 A Randomized 3-Arm Phase II study comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib, and 3.) Bendamustine, Rituximab and Acalabrutinib in patients < 70 years old with untreated Mantle Cell Lymphoma
  • S1826    A Phase III, randomized study of Nivolumab plus AVD or Brentuximab Vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma

Melanoma & Skin

  • EA6134 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
  • EA6191 The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double-Blind Phase II study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K melanoma with elevated LDH2
  • S1801 A Phase II Randomized Study of Adjuvant Vs. Neoadjuvant MK-3475 (Pembrolizumab) for clinically Detectable Stage III-IV High Risk Melanoma
  • S2000 A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF V6000 Mutant Melanoma with brain Metastases
  • A091802   Phase II Randomized trial of Avelumab Plus Cetuximab versus Avelumab alone in advanced cutaneous squamous cell carcinoma of the skin
  • EA6174  STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III trial

Multiple Myeloma

  • EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma
  • EAA181 Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
  • S1803 Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma using minimal residual disease to direct therapy duration (DRAMMATIC Study)


  • S1701  A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

All Disease Types

  • NCICOVID NCI COVID-19 in cancer patients study (N-CCaPS): A longitudinal natural history study
  •  U16092  Phase II Study of Low-Dose Ibuprofen for Cognitive Problems In Patients With Non Metastatic Cancer
  • A151804 Establishment of a National Biorepository to Advance Studies of Immune Related Adverse Events
  • DCP001 Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
  • S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors